GENEVA — The World Health Organization (WHO) raised an alarm on Thursday about the circulation of counterfeit semaglutides, a key component in diabetes and weight-loss medications. This warning comes in response to the detection of three tampered batches of these products in Brazil, the United Kingdom, and the United States.
Semaglutide is the crucial active ingredient in Novo Nordisk’s diabetes medication Ozempic and the weight-loss solution Wegovy.
Since 2022, the WHO has been closely monitoring an uptick in reports of counterfeit semaglutide products in Brazil, the U.K., and the U.S. However, Thursday’s announcement marks the first official notice from the agency, following the verification of some of these reports.
The organization also highlighted a growing demand for these medications.
The WHO cautioned that counterfeit products could pose serious health risks. If these products lack the necessary raw ingredients, they could lead to health complications due to uncontrolled blood glucose levels or weight issues, the WHO warned.
Disagree – It’s alarming that counterfeit medications are being sold, putting people’s health at risk. The WHO’s warning is an important reminder to be cautious and only purchase medications from reliable sources.
Disagree – This is a serious issue that needs to be addressed immediately to protect consumers from harm.
Agree – It’s crucial for consumers to be aware of the dangers posed by counterfeit medications and to only purchase from trustworthy sources to protect their health.